AZ's China R&D strategy calls for outsourcing

AstraZeneca's $100 million R&D strategy for China includes a significant focus on outsourcing in Asia. Research chief Steve Yang says AstraZeneca ($AZN) doesn't want to simply replicate the work it does in the U.S. and Europe. By taking what they know about biomarkers and patient selection, its investigators want to craft a new approach that targets specific disease challenges--such as high rates of gastric and liver cancers--and builds on its tech skills. And to maximize efficiency, the company wants to pursue R&D outsourcing as it forges new research ties with academic groups as well as biotech companies. Story

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.